Dyne Therapeutics price target raised to $66 from $41 at Stifel

Stifel raised the firm’s price target on Dyne Therapeutics to $66 from $41 and keeps a Buy rating on the shares after sitting down with management to discuss their DMD/DM1 programs and what the path forward may look like. Management remains confident FORCE has a differentiated therapeutic index as the company continues to dose higher in both studies with no issues, and continues to believe accelerated paths on dystrophin/splicing remain on the table, the analyst tells investors in a research note. The firm says management continues to engage with regulators and will describe path-to-market for both programs by year-end.